Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A large language model for complex cardiology care.

Nature medicine·2026
Same author

Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapy.

Molecular therapy. Nucleic acids·2025
Same author

Predicting LVEF After PCI and its Effect on Clinical Outcomes in Patients With Stable Ischemic Cardiomyopathy and LVEF≤50.

The American journal of cardiology·2025
Same author

Differential Selection of Obesity Treatments by Race/Ethnicity: Insights From the Veterans Affairs Healthcare System.

JACC. Advances·2025
Same author

Reversed Remodeling Unveils Mitral Annular Disjunction.

JACC. Case reports·2025
Same author

Performance of the Monoclonal Antibody B72.3 in Diagnosis of Malignant Carcinomatous Serous Effusions-A Systematic Review and Meta-Analysis of Diagnostic Performance.

Cytopathology : official journal of the British Society for Clinical Cytology·2025

Related Experiment Videos

Current and future uses of nesiritide.

Robert E Hobbs1, Wilson Tang

  • 1hobbsr@ccf.org

Future Cardiology
|October 7, 2009
PubMed
Summary
This summary is machine-generated.

Nesiritide, a B-type natriuretic peptide, effectively treats acutely decompensated heart failure by reducing heart pressures and improving cardiac function. Ongoing trials investigate its use in diverse clinical scenarios and alternative delivery methods.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acutely decompensated heart failure (ADHF) presents significant clinical challenges.
  • Nesiritide, a recombinant human B-type natriuretic peptide (BNP), offers a therapeutic option for ADHF.

Purpose of the Study:

  • To summarize the therapeutic effects of nesiritide in ADHF.
  • To review ongoing research into nesiritide's potential benefits in various clinical settings.

Main Methods:

  • Review of existing clinical data and ongoing trials concerning nesiritide.
  • Analysis of nesiritide's pharmacological actions, including hemodynamic and symptomatic improvements.

Main Results:

  • Nesiritide demonstrates efficacy in reducing intracardiac filling pressures and increasing cardiac index.
  • It provides symptomatic relief for patients with ADHF.
  • Emerging data suggest potential benefits in peri-operative settings, chronic infusions, and specific patient populations.

Conclusions:

  • Nesiritide is a valuable intravenous vasodilator for ADHF.
  • Further research is exploring its expanded therapeutic applications and delivery methods.